Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 2068 Radiotherapy 1990 Cisplatin 1857 Carboplatin 1560 Gemcitabine 1455 Paclitaxel 1322 Bevacizumab 1321 pembrolizumab 1240 Docetaxel 1227 Oxaliplatin 1184 Capecitabine 1179 Fluorouracil 1083 Dexamethasone 979 Magnetic Resonance Spectroscopy 973 Nivolumab 936 Rituximab 929 Drug Therapy 915 Surveys and Questionnaires 899 Doxorubicin 845 Etoposide 843 Radiosurgery 816 Blood Specimen Collection 816 Irinotecan 784 Cytarabine 743 fludarabine 726 Leucovorin 684 Surgical Procedures, Operative 641 Lenalidomide 619 Biopsy 595 Specimen Handling 570

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡